BTIG Research Downgrades Carisma Therapeutics (NASDAQ:CARM) to Neutral

BTIG Research lowered shares of Carisma Therapeutics (NASDAQ:CARM) from a buy rating to a neutral rating in a research report released on Tuesday morning, Marketbeat Ratings reports.

CARM has been the subject of several other reports. HC Wainwright cut their price objective on Carisma Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a report on Monday, November 25th. D. Boral Capital cut their price target on Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating for the company in a research note on Monday. Finally, EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $4.94.

Carisma Therapeutics Trading Down 12.8 %

NASDAQ:CARM opened at $0.49 on Tuesday. The stock has a market cap of $20.25 million, a PE ratio of -0.31 and a beta of 1.44. Carisma Therapeutics has a fifty-two week low of $0.46 and a fifty-two week high of $3.16. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. The stock’s 50-day moving average is $0.91 and its two-hundred day moving average is $1.04.

Carisma Therapeutics (NASDAQ:CARM) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. The firm had revenue of $3.39 million for the quarter. As a group, equities research analysts forecast that Carisma Therapeutics will post -1.32 earnings per share for the current fiscal year.

Institutional Trading of Carisma Therapeutics

Several large investors have recently made changes to their positions in CARM. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Carisma Therapeutics in the 2nd quarter worth approximately $40,000. Wexford Capital LP raised its position in shares of Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after purchasing an additional 15,000 shares during the period. Barclays PLC lifted its stake in shares of Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after buying an additional 549,290 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Carisma Therapeutics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock worth $3,587,000 after buying an additional 11,200 shares during the period. Institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.